Get all your news in one place.

100's of premium titles.
One app.

Start reading

Get all your news in one place.

100's of premium titles. One news app.

Start reading

UNCOVERED: 13 - Caught on Camera

George Hincapie's new Modern Adventure team: Renaissance or more of the same? - Opinion

Has the spectre of Lance Armstrong's doping evaporated or will it come back to haunt the new squad?

Cycling News

HIMS Crashes On Novo GLP-1 Fallout: Buy The Dip Or Bail?

Telehealth darling Hims Hers Health Inc (NYSE:HIMS) got slapped with a 34% stock crash on Monday. Novo Nordisk A/S (NYSE:NVO) ended their relationship – and it wasn't amicable.

Benzinga

Why Did Novo Nordisk Pull the Plug on Hims Collaboration?

Novo Nordisk ended its partnership with Hims & Hers on 23 June 2025, accusing the telehealth firm of selling unsafe, unapproved Wegovy knock-offs. Hims' stock tanked, and legal risks loom.

International Business Times UK

From analysis to the latest developments in health,
read the most diverse news in one place.

World shares rally after Trump announces what appears to be a shaky Israeli-Iran ceasefire

Stock markets have rallied and oil prices fell after U.S. President Donald Trump announced what appears to be a shaky ceasefire in the Israel-Iran conflict

The Independent UK

Hims CEO Slams Novo Nordisk For 'Anticompetitive Demands' After Ozempic Maker Abruptly Ends Partnership: 'We Refuse To Be Strong-Armed'

Hims Hers Health Inc. (NYSE:HIMS), CEO Andrew Dudum, has accused Novo Nordisk of exerting anticompetitive pressure to prioritize its weight-loss drug Wegovy over patient needs after the abrupt termination of its partnership with a pharmaceutical giant.

Benzinga

Novo Nordisk Just Axed Its Deal with Hims & Hers. Should You Buy the Dip in HIMS Stock?

Hims & Hers stock tumbles as Novo Nordisk terminates Wegovy deal. BofA warns of significant further downside in the HIMS share price.

Barchart

Hims Stock Tumbles Down After Abrupt Exit of Novo Nordisk: Here's Everything That Went Wrong

Novo Nordisk alleged that some telehealth entities, including Hims & Hers, used illicit semaglutide sourced from unregulated Chinese manufacturers not approved or inspected by the FDA.

International Business Times UK

Read news from The Economist, FT, and more,
with one subscription

Hims & Hers stock drops after Wegovy manufacturer ends deal to distribute weight loss drug

Hims & Hers had partnered with the Danish pharmaceutical giant in April to sell Wegovy

The Independent UK

Hims & Hers Health Stock Is Tumbling Monday: What's Happening?

Hims Hers Health Inc (NYSE:HIMS) shares are trading lower Monday after Novo Nordisk A/S (NYSE:NVO) terminated its collaboration with the company.

Benzinga

Novo Nordisk is losing Canadian patent protection on a blockbuster drug after not paying a small fee

“I’m sure someone’s lost their job,” said the CEO of Sandoz, which has now filed to launch a generic GLP-1 drug in Canada next year.

Fortune

From AI to aerospace: Europe's most innovative companies shaping tomorrow

For the first time, Fortune analyzed the top companies across the continent in partnership with Statista to find the standouts that are driving progress with success.

Fortune

With Novo Nordisk's CEO Out, Wall Street Wants an American Leader

With its stock plummeting over the past year, Novo Nordisk is waving goodbye to its top executive. What might the future hold for the weight-loss drug kingpin?

MarketBeat

Breaking Down Thursday’s Top 3 Unusually Active Options

In Thursday’s unusual options activity, there were 1,399, split almost evenly between puts (705) and calls (694). Of the top 100 by Vol/OI ratios, the top three ratios range from 81.86 to 69.31.

Barchart

Weight loss drugs linked to higher risk of eye damage in diabetic patients

Study finds medicines such as Ozempic associated with greater risk of developing age-related macular degeneration

The Guardian - UK

Get all your
news in one place.

100's of premium titles.
One news app.

Cycling News

Tudor Pro, Uno-X and TotalEnergies scheduled to debut in Maryland Cycling Classic in September

Early commitments for women's race include Canyon-SRAM zondacrypto and EF Education-Oatly

Barchart

Eli Lilly vs. Novo Nordisk: Which Stock Is the Winner of the Weight-Loss Drug Boom?

Both companies have established a solid presence in the weight-loss drug market, but only one of them can lead.

Fortune

The boomerang era: A slew of former CEOs are suiting up once more to take top roles at their old companies

From Novo Nordisk to UnitedHealth, onetime chief executives are returning to guide their former organizations in times of trouble.

MarketBeat

Analysts Think These Stocks Could More Than Double in Value

Septerna, Intellia, and Novavax have garnered investor attention for their significant upside potential, but investors should beware the risks as well.

Get all your
news in one place.

100's of premium titles.
One news app.

The Independent UK

Lawsuits are piling up as weight-loss drug users report losing their sight: ‘I definitely wouldn’t have taken it’

Edward Fanelli, 57, shared his regrets about taking Ozempic after he was diagnosed with a rare eye condition.

Barchart

Jim Cramer Says You Should Buy This ‘Strong Buy’ Stock ‘Hand Over Fist’

Cramer explains why this pharmaceutical company is a buy as it outperforms a key rival.

Kiplinger

Stock Market Today: Investors Look on the Bright Side

A generally good week closes on another positive note, as investors, traders and speculators look for fresh catalysts.

Barchart

Is Novo Nordisk Stock a Buy, Sell, or Hold as CEO Lars Fruergaard Jørgensen Resigns?

Novo Nordisk stock sinks as CEO Lars Fruergaard announces his resignation. Analysts are not happy with his departure but continue to see significant upside in NVO shares.

International Business Times

Ozempic-maker Novo Nordisk Says CEO To Step Down

Danish drugmaker Novo Nordisk, known for its blockbuster diabetes and weight-loss treatments Ozempic and Wegovy, said Friday its chief executive was stepping down in the wake of "market challenges".

Euronews

Novo Nordisk CEO steps down amid growing competition for weight loss drugs

Lars Fruergaard Jørgensen, who has led the pharmaceutical giant since 2017, joined the firm in 1991.

MarketBeat

Is It Time to Buy the Dip in Novo Nordisk Stock?

Novo Nordisk stock is down nearly 50% in 2025 as competition in the GLP-1 space continues to mount, but the fundamental case for the NVO stock is growing

1 … 12 13 14 15

People

Lars Fruergaard Jørgensen

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.